|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Japanese Gastric Cancer Association:
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
3
|
Anderson AC: Tim-3: An emerging target in
the cancer immunotherapy landscape. Cancer Immunol Res. 2:393–398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin DS and Ribas A: The evolution of
checkpoint blockade as a cancer therapy: What's here, what's next?
Curr Opin Immunol. 33:23–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geng H, Zhang GM, Li D, Zhang H, Yuan Y,
Zhu HG, Xiao H, Han LF and Feng ZH: Soluble form of T cell Ig mucin
3 is an inhibitory molecule in T cell-mediated immune response. J
Immunol. 176:1411–1420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang J, Zhu L, Cai Y, Suo J and Jin J:
Role of downregulation of galectin-9 in the tumorigenesis of
gastric cancer. Int J Oncol. 45:1313–1320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takano J, Morishita A, Fujihara S, Iwama
H, Kokado F, Fujikawa K, Fujita K, Chiyo T, Tadokoro T, Sakamoto T,
et al: Galectin-9 suppresses the proliferation of gastric cancer
cells in vitro. Oncol Rep. 35:851–860. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fontenot JD, Rasmussen JP, Williams LM,
Dooley JL, Farr AG and Rudensky AY: Regulatory T cell lineage
specification by the forkhead transcription factor foxp3. Immunity.
22:329–341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun X, Feng Z, Wang Y, Qu Y and Gai Y:
Expression of Foxp3 and its prognostic significance in colorectal
cancer. Int J Immunopathol Pharmacol. 30:201–206. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nosho K, Baba Y, Tanaka N, Shima K,
Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS and
Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in
colorectal cancer, and prognosis: Cohort study and literature
review. J Pathol. 222:350–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szasz AM, Lanczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A,
Michalowski A and Green JE: A gene expression signature of acquired
chemoresistance to cisplatin and fluorouracil combination
chemotherapy in gastric cancer patients. PLoS One. 6:e166942011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB,
Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic
pathway combinations predict clinical prognosis in gastric cancer.
PLoS Genetics. 5:e10006762009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forster S, Gretschel S, Jons T, Yashiro M
and Kemmner W: THBS4, a novel stromal molecule of diffuse-type
gastric adenocarcinomas, identified by transcriptome-wide
expression profiling. Mod Pathol. 24:1390–1403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang G, Hu N, Yang HH, Wang L, Su H, Wang
C, Clifford R, Dawsey EM, Li JM, Ding T, et al: Comparison of
global gene expression of gastric cardia and noncardia cancers from
a high-risk population in china. PLoS One. 8:e638262013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Busuttil RA, George J, Tothill RW,
Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I and
Boussioutas A: A signature predicting poor prognosis in gastric and
ovarian cancer represents a coordinated macrophage and stromal
response. Clin Cancer Res. 20:2761–2772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanchez-Fueyo A, Tian J, Picarella D,
Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T,
Kuchroo VK, et al: Tim-3 inhibits T helper type 1-mediated auto-
and alloimmune responses and promotes immunological tolerance. Nat
Immunol. 4:1093–1101. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sabatos CA, Chakravarti S, Cha E, Schubart
A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ and
Kuchroo VK: Interaction of Tim-3 and Tim-3 ligand regulates T
helper type 1 responses and induction of peripheral tolerance. Nat
Immunol. 4:1102–1110. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia
Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased
Tim-3 expression are related to poor prognosis in gastric cancer.
PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu Y, Zhang H, Huang Y, Rui X and Zheng F:
Role of TIM-3 in ovarian cancer. Clin Transl Oncol. 19:1079–1083.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ngiow SF, Teng MW and Smyth MJ: Prospects
for TIM3-targeted antitumor immunotherapy. Cancer Res.
71:6567–6571. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
da Silva IP, Gallois A, Jimenez-Baranda S,
Khan S, Anderson AC, Kuchroo VK, Osman I and Bhardwaj N: Reversal
of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Cancer Immunol Res. 2:410–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson AC: Tim-3, a negative regulator
of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang X, Jiang X, Chen G, Xiao Y, Geng S,
Kang C, Zhou T, Li Y, Guo X, Xiao H, et al: T cell Ig mucin-3
promotes homeostasis of sepsis by negatively regulating the TLR
response. J Immunol. 190:2068–2079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu FT and Rabinovich GA: Galectins as
modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Szoke T, Kayser K, Baumhakel JD, Trojan I,
Furak J, Tiszlavicz L, Horvath A, Szluha K, Gabius HJ and Andre S:
Prognostic significance of endogenous adhesion/growth-regulatory
lectins in lung cancer. Oncology. 69:167–174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cedeno-Laurent F and Dimitroff CJ:
Galectins and their ligands: Negative regulators of anti-tumor
immunity. Glycoconj J. 29:619–625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ohue Y, Kurose K, Nozawa R, Isobe M,
Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M and Nakayama
E: Survival of lung adenocarcinoma patients predicted from
expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on tumor cells
and tumor-infiltrating T cells. Cancer Immunol Res. 4:1049–1060.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seki M, Oomizu S, Sakata KM, Sakata A,
Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, et al:
Galectin-9 suppresses the generation of Th17, promotes the
induction of regulatory T cells, and regulates experimental
autoimmune arthritis. Clin Immunol. 127:78–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamauchi A, Kontani K, Kihara M, Nishi N,
Yokomise H and Hirashima M: Galectin-9, a novel prognostic factor
with antimetastatic potential in breast cancer. Breast J. 12 5
Suppl 2:S196–S200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang M, Ueno M, Oomizu S, Arikawa T,
Shinonaga R, Zhang S, Yamauchi A and Hirashima M: Galectin-9
expression links to malignant potential of cervical squamous cell
carcinoma. J Cancer Res Clin Oncol. 134:899–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kawazoe A, Kuwata T, Kuboki Y, Shitara K,
Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A and Ochiai A:
Clinicopathological features of programmed death ligand 1
expression with tumor-infiltrating lymphocyte, mismatch repair, and
Epstein-Barr virus status in a large cohort of gastric cancer
patients. Gastric Cancer. 20:407–415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS,
Lee BL and Kim WH: Prognostic implications of type and density of
tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer.
99:1704–1711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Reuver PR, Mehta S, Gill P, Andrici J,
D'Urso L, Clarkson A, Mittal A, Hugh TJ, Samra JS and Gill AJ:
Immunoregulatory forkhead box protein p3-positive lymphocytes are
associated with overall survival in patients with pancreatic
neuroendocrine tumors. J Am Coll Surg. 222:281–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Frydrychowicz M, Boruczkowski M,
Kolecka-Bednarczyk A and Dworacki G: The dual role of Treg in
cancer. Scand J Immunol. 86:436–443. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hou J, Yu Z, Xiang R, Li C and Wang L,
Chen S, Li Q, Chen M and Wang L: Correlation between infiltration
of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor
tissues of gastric cancer. Exp Mol Pathol. 96:284–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cimino-Mathews A, Thompson E, Taube JM, Ye
X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, et al:
PD-L1 (B7-H1) expression and the immune tumor microenvironment in
primary and metastatic breast carcinomas. Hum Pathol. 47:52–63.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Z, Zhu J, Gu H, Yuan Y, Zhang B, Zhu
D, Zhou J, Zhu Y and Chen W: The clinical significance of abnormal
Tim-3 expression on NK cells from patients with gastric cancer.
Immunol Invest. 44:578–589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng G, Li M, Wu J, Ji M, Fang C, Shi H,
Zhu D, Chen L, Zhao J, Shi L, et al: Expression of Tim-3 in gastric
cancer tissue and its relationship with prognosis. Int J Clin Exp
Pathol. 8:9452–9457. 2015.PubMed/NCBI
|
